Pre-seed open · 12 months to first market AVIX Pharmaceuticals Limited · United Kingdom & Bangladesh
Evidence

Proof of concept.
Clearly shown.
Carefully stated.

What we tested, what we found, what it means and what it does not mean. We would rather be believed than impressive.

Disc diffusion plate with zones of inhibition expanding around five test discs
01 ·Disc diffusion on clinical isolates

Five matched test conditions, compared on both plates.

MRSA and MDR S. typhi were tested using the same five disc conditions, allowing a direct side-by-side comparison of measured inhibition zones.

Agar plate of methicillin-resistant Staphylococcus aureus showing clear zones of inhibition around the plant-derived discs
Plate A

MRSA · S. aureus

Methicillin-resistant Staphylococcus aureus. The chemical comparator discs show little measurable clearance, while the three-compound condition produces the widest zone.

1–2 Chemical antibiotics, 30 µg3 Single compound4 Two compounds5 Three compounds — 15 mm
Agar plate of multidrug-resistant Salmonella Typhi showing clear zones of inhibition around the plant-derived discs
Plate B

MDR S. typhi

Multidrug-resistant Salmonella enterica serotype Typhi. The same five-condition sequence is shown, with the three-compound condition reaching the largest measured inhibition zone.

1–2 Chemical antibiotics, 30 µg3 Single compound4 Two compounds5 Three compounds — 20 mm
Measured results

Same five conditions. Two resistant clinical isolates.

Zone of inhibition (mm)
Measured disc diffusion results for five matched conditions against MRSA and multidrug-resistant Salmonella Typhi

Within the same assay, larger zones indicate greater inhibition. Compound identities and exact formulation ratios remain confidential pending patent filing.

Method and result

What we tested and what the plates show.

Method. Forty-one candidate combinations were screened against clinical MRSA and multidrug-resistant S. typhi. The two chemical comparator conditions used 30 µg; the single, dual and triple plant-derived conditions used 600 µg per component.

Result. The two chemical comparators produced 1–7 mm zones. Activity increased from the single condition to the dual and triple cocktails, reaching 15 mm against MRSA and 20 mm against S. typhi.

Shared method. Disc diffusion and Agar Well Diffusion Method repeated assays. Numbered discs represent the same five test conditions on both plates. Compound identities and ratios are withheld pending patent filing; the photographs are our own and the labels were redrawn for clarity.

The horizontal scale starts at zero. Zone diameter is not dose-normalised potency and does not establish equivalence between the comparator and plant-derived conditions.

Horizontal comparison of MRSA and multidrug-resistant Salmonella Typhi inhibition zones across the five matched test conditions
02 ·Interpretation

Credible proof of concept, not animal efficacy.

Repeated inhibition of two multidrug-resistant clinical isolates justifies the next validation stage.

The funded work must add MIC/MBC, time-kill, resistance development, mechanism, safety, stability, live-bird evidence, independent replication and peer review.

Next studies

What the funded phase produces

  • MIC/MBC and time-kill testing across more isolates
  • Resistance-development and mechanism assays
  • Initial cytotoxicity, formulation and stability
  • Controlled broiler study to EFSA data standards
  • Independent CRO verification
03 ·Target product profile

What we are building towards.

This is the specification a Green Antibiotics product must meet before market entry. Every line is a target with a study attached, not a result already held.

Target 01

Residue clearance

No accumulation in meat or eggs; assessed through residue analysis in the broiler study.

Target 02

No-withdrawal goal

Use through to slaughter; assessed through depletion data and regulatory classification.

Target 03

Dose tolerance

Normal health and performance at the intended dose; assessed in safety and tolerance arms.

Target 04

Lead stability

Seven characterised, shelf-stable cocktails; assessed through MIC panels and stability testing.

Development boundary

Every item above remains a target until residue, tolerance, stability and regulatory studies convert it into evidence.

Essential-oil compounds can be concentration-dependent and formulation-sensitive.17

04 ·Data access

Full data set available under NDA.

Raw plate images, measurement tables, repeat data and the screening protocol are available to investors, partners and scientific collaborators on request.

Discipline about failure

Thirty-four of forty-one did not progress

We publish the denominator, not only the seven leads. A screening claim without its denominator is a marketing claim. This is the standard the founders would apply to a pharmaceutical programme, and the fastest way to judge whether a signal is real.

Scientific references1 source used on this page
17

Alves-Silva J M, Zuzarte M, Girão H, Salgueiro L, et al.

Alves-Silva J M, Zuzarte M, Girão H, Salgueiro L, et al. Reviews on the antimicrobial efficacy, volatility, instability and concentration-dependent toxicity of essential-oil compounds in animal production, including microencapsulation as a mitigation strategy. Antibiotics, 14(6):552, 2025. mdpi.com/2079-6382/14/6/552

From evidence to development

The next question is which leads can become practical animal-health products.

See the lead portfolio, market logic and commercial pathway.